Marksans Pharma Ltd

MARKSANS

Watchlist

AI Mode

‌

Market Cap

₹ 8,646 Cr

P/E

24.59

Turned 1 L into 3.09 L in last 3 Years

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bullish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Marksans Pharma Limited engages in research, manufacture, marketing, and sale of pharmaceutical formulations, with a significant footprint in the OTC segment across major markets like the US and UK.

Q2 FY26 saw a 16% sequential revenue growth driven by robust demand across key markets, bolstered by new product launches and improved operational execution.

Management attributes strong revenue growth to strategic order book execution, noted especially in the US, which constitutes 53% of total revenue, up by 27% YoY.

A planned capacity expansion in their Goa plant to 1.3 billion tablets showcases strategic foresight to meet projected revenue targets of up to ₹4,000 crore.

The company remains committed to strategic acquisitions, evidenced by recent M&A activities, to scale operations and enhance market presence in emerging markets.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

8,646 Cr

Volatility

High Risk

P/E Ratio

24.6

Industry P/E

43.8

PEG Ratio

1.4

P/B Ratio

3.2

52W High

332.20

52W Low

162.05

Sales CAGR

20.46%

21.28%

22.06%

10Y

14.11%

Profit CAGR

21.51%

21.88%

37.79%

10Y

11.36%

ROE

TTM

13.08%

15.15%

16.31%

10Y

15.37%

ROCE

TTM

16.13%

18.79%

20.44%

1Y Price Target

237.66 ▲ 26.92%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
CAPLIPOINT	1957.00	14,864 Cr	25.24	4.70	0.31	18.64	23.29	17.02
RUBICON	634.55	10,481 Cr	78.34	10.03	0.00	41.49	34.93	8.82
MARKSANS	190.80	8,646 Cr	24.59	3.22	0.42	13.08	16.13	10.26
SHILPAMED	323.00	6,333 Cr	40.94	2.60	0.15	6.35	8.41	3.93
SPARC	136.30	4,423 Cr	—	0.00	0.00	77.47	-181.73	-82.81
SENORES	818.00	3,756 Cr	43.11	4.61	0.00	10.70	12.41	6.65
SHUKRAPHAR	53.71	2,352 Cr	198.93	35.74	0.02	18.17	20.39	13.71

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	500	531	586	560	591	642	682	708	620	720
Expenses	398	417	453	450	462	506	543	583	520	576
Operating Profit	102	114	133	110	128	136	139	126	100	144
OPM %	20.39	21.45	22.69	19.58	21.74	21.14	20.35	17.75	16.15	20.06
Other Income	10	19	4.80	17	15	11	28	17	5.64	22
Interest	1.58	1.63	3.16	4.84	2.92	2.63	2.67	3.44	6.07	5.82
Depreciation	14	18	22	21	20	20	21	23	23	27
Profit Before Tax	97	114	113	100	120	125	143	116	77	133
Tax %	27.25	26.30	26.35	22.57	25.79	21.54	26.66	21.85	24.02	25.65
Net Profit	70	84	83	78	89	98	105	91	58	99
EPS in Rs	1.52	1.84	1.84	1.73	1.96	2.13	2.31	2.00	1.29	2.17

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	767	913	1,000	1,134	1,376	1,491	1,852	2,177	2,623	2,652
Expenses	722	826	868	942	1,037	1,232	1,513	1,719	2,094	2,152
Operating Profit	45	86	132	192	340	259	339	459	529	500
OPM %	5.83	9.48	13.21	16.95	24.68	17.36	18.32	21.06	20.16	18.86
Other Income	7.02	0.36	4.62	0.33	6.69	42	59	50	70	61
Interest	6.78	10	9.66	8.75	7.99	8.45	9.13	11	12	15
Depreciation	30	27	23	27	36	45	52	74	83	86
Profit Before Tax	15	50	104	157	302	248	338	424	504	461
Tax %	23.92	28.11	22.88	23.17	21.06	24.52	21.42	25.65	24.08	23.62
Net Profit	11	36	80	121	239	187	265	315	383	352
EPS in Rs	0.33	0.72	1.69	2.58	5.20	4.07	6.04	6.93	8.40	7.77
Dividend Payout %	22.73	6.25	2.67	3.39	4.34	5.54	7.80	8.67	9.52	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	41	41	41	41	41	41	41	45	45	45
Reserves	401	393	430	502	595	846	1,161	1,700	2,020	2,422
Borrowings	100	110	117	100	30	34	111	123	244	322
Other Liabilities	180	209	141	161	237	308	327	322	372	451
Total Liabilities	722	752	729	804	903	1,229	1,640	2,190	2,681	3,240
Fixed Assets	270	267	279	270	303	309	428	486	776	982
CWIP	0.00	0.36	0.00	0.00	0.00	12	2.57	9.87	9.42	27
Investments	0.00	0.00	0.00	0.00	0.00	0.26	0.44	0.54	27	0.74
Other Assets	452	484	450	534	600	908	1,209	1,694	1,869	2,230
Total Assets	722	752	729	804	903	1,229	1,640	2,190	2,681	3,240

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	31	14	59	27	233	179	99	237	230	207
Cash from Investing Activity	-123	-21	-39	-13	-60	-45	-84	-259	-141	-49
Cash from Financing Activity	-58	-3.47	-5.43	-21	-114	-15	80	198	-69	-65
Net Cash Flow	-150	-10	15	-6.86	60	118	94	176	21	93

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jan 2023	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	43.80%	43.85%	43.85%	43.85%	43.85%	43.85%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
FIIs	14.83%	15.12%	14.91%	15.07%	15.56%	15.57%	18.60%	21.31%	21.96%	22.20%	19.88%	16.92%
DIIs	0.87%	1.46%	3.65%	4.02%	4.76%	5.17%	3.75%	4.10%	4.30%	4.56%	5.50%	5.28%
Public	40.50%	39.58%	37.59%	37.06%	35.83%	35.40%	33.78%	30.71%	29.87%	29.37%	30.75%	33.93%
Total Shareholders	2,09,299	1,98,382	1,88,447	2,07,937	2,37,377	2,54,699	2,35,500	2,48,845	2,59,813	2,57,273	2,56,221	2,65,788

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Jul 28, 2025	Unifi capital private limited	Bulk	Buy	231.50	167.64 Cr	72,41,309	1.59
Jun 11, 2025	Orbimed asia iv mauritius fvc...	Bulk	Sell	249.95	256.78 Cr	1,02,73,443	2.26
Jun 11, 2025	Unifi blend fund 2	Bulk	Buy	249.95	74.99 Cr	30,00,000	0.66
Jun 11, 2025	Unifi capital private limited...	Bulk	Buy	249.95	81.17 Cr	32,47,600	0.71
Jun 11, 2025	Bandhan mutual fund	Block	Buy	249.95	15.00 Cr	6,00,000	0.13
Jun 11, 2025	Unifi capital private limited...	Block	Buy	249.95	81.17 Cr	32,47,600	0.71
Jun 11, 2025	Uti mutual fund	Block	Buy	249.95	10.35 Cr	4,14,093	0.09
Jun 11, 2025	Unifi capital private limited	Block	Buy	249.95	14.85 Cr	5,94,000	0.13
Jun 11, 2025	Subhkam ventures i private li...	Block	Buy	249.95	13.43 Cr	5,37,485	0.11
Jun 11, 2025	Unifi blend fund 2	Block	Buy	249.95	74.99 Cr	30,00,000	0.66

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Investor Presentation

Q2 FY24

Showing 1 - 8 of 25

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Marksans

Marksans Pharma Ltd

MARKSANS

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Oscillators

Neutral

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Forecasts

10

237.66 ▲ 26.92%

Upgrade

Upgrade

Upgrade

Upgrade

Unlock Premium Features

Upgrade

Buy

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Unlock Premium Features

Upgrade

Actions

Announcements

Documents

AI Mode

AI Mode

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Peers

Price Chart Comparison

Investment Checklist